Prevalence of Potentially Inappropriate Treatments (INAPPT-ICU)

February 28, 2019 updated by: ELIF ERDOGAN, Istanbul University

Potentially Inappropriate Treatments in Turkish ICUs: Point Prevalence Study

A multicenter point prevalence study in Turkish intensive care units.

Study Overview

Detailed Description

Intensive care units (ICU) are life-saving units for critical patients with using advanced technology. In some cases, it becomes a unit where treatment is not possible, the fatal patients are admitted and the death process is extended. Most patients with end-stage cancer, advanced-stage chronic obstructive pulmonary disease (COPD) and advanced-stage Alzheimer's disease prefer to die at home, although many often refer to emergency services at the end of their life and are then transferred to the ICU. Intensive care treatments are often very invasive and painful interventions. The patient who lives in intensive care unit is faced with many psychological distresses such as communication, isolation and fear besides physical ache. For this reason, it is necessary to make decisions (end-of-life decisions) such as forbearing intensive care treatments applied to the patients in the death process or cutting out the ones started. In the world, the goal for the end of life patients is, improving the last phase of their lives with the application of these decisions and symptom therapy, living in a peace without pain and respiratory distress. However, there is an uncertanity in these issues in our country and intensive care physicians are hesitant to make decisions about the end of life with concern about legal problems. Although it is known that these patients will not benefit most from the treatment of ICU, they are getting treatments for saving their lives in ICUs. The fact that intensive care beds are not available due to the patients who are not get beneficial treatment, brings the result of difficult finding of the beds which will benefit from the intensive care, and in fact it is a waste of intensive care resources which is very expensive. The size of the problem is not known as there is no data on the frequency of patients in our country who are in intensive care and require end-of-life care.

In this multicenter point prevalence study our aims are;

  • to find out the incidence of patients in intensive care units in Turkey in the last period of life,
  • to compare the resource use of end-of-life and non-end-of-life patients.

Study Type

Observational

Enrollment (Actual)

1128

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Istanbul, Turkey
        • İstanbul University Cerrahpaşa Medical School

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

All intensive care patients fulfilling eligibility criteria

Description

Inclusion Criteria:

All patients who are over 18 years old, more than 48 hours in the intensive care unit, or expected to be hospitalized

Exclusion Criteria:

Patients under 18 years of age, less than 48 hours in the intensive care unit stay, or who are monitorized for post-operative care

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Prevalence of terminal patients in the ICU
Time Frame: 1 day
Investigation of the number of terminal patients treated in the intensive care units at the last days of life
1 day

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Resource use
Time Frame: 1 day
Comparison of treatment implementations such as antibiotics, use of mechanical ventilation, renal replacement therapy, nutrition and blood transfusions and their estimated costs, used for terminal and non-terminal patients
1 day

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 15, 2018

Primary Completion (Actual)

November 14, 2018

Study Completion (Actual)

November 30, 2018

Study Registration Dates

First Submitted

April 13, 2018

First Submitted That Met QC Criteria

April 26, 2018

First Posted (Actual)

May 9, 2018

Study Record Updates

Last Update Posted (Actual)

March 1, 2019

Last Update Submitted That Met QC Criteria

February 28, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Other Study ID Numbers

  • EERDOGAN

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Critical Illness

3
Subscribe